Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical company advancing targeted protein degradation therapies for immune-inflammatory diseases and oncology. This dedicated news hub provides investors and industry observers with timely updates on the company’s scientific progress, clinical developments, and strategic initiatives.
Access comprehensive coverage of KYMR’s innovative pipeline, including updates on STAT6 and IRAK4 degrader programs, partnership announcements, and financial disclosures. Our curated news collection enables efficient tracking of milestones in protein degradation research – from preclinical breakthroughs to clinical trial results – while maintaining strict adherence to factual reporting standards.
Key content categories include regulatory filings, peer-reviewed research highlights, executive leadership updates, and analysis of therapeutic platform advancements. All materials are sourced from verified channels to ensure reliability for investment research and sector analysis.
Bookmark this page for streamlined access to KYMR’s latest developments in transforming undruggable targets into viable treatment pathways through proprietary degradation technology. Check regularly for updates on oral small molecule therapies that aim to combine biologics-like efficacy with enhanced patient convenience.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in three major investor conferences in June 2025:
- Jefferies Global Healthcare Conference in New York on June 5 at 8:10 a.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 10 at 3:20 p.m. ET
- Wolfe Research Virtual Biotech Day on June 26 (one-on-one meetings only)
Live webcasts of the presentations will be available on Kymera's website under the Investors section, with replays archived for later viewing.
- Achieved >90% degradation across multiple species with low oral doses
- Demonstrated superior efficacy to current standards in lupus and RA models
- Showed favorable safety profile up to 200-fold projected human efficacious levels
- Effectively blocked multiple inflammatory pathways in patient samples
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in the BofA Securities 2025 Healthcare Conference. The company will engage in a fireside chat on May 14, 2025, at 3:40 p.m. PT in Las Vegas, NV. Investors can access a live webcast of the presentation through the \"News and Events\" section of Kymera's website, with a replay available after the event.
Kymera Therapeutics (NASDAQ: KYMR) has scheduled a video webcast for May 9, 2025, from 10:00 a.m. to 11:30 a.m. ET. During this event, the clinical-stage biopharmaceutical company will:
- Present its Q1 2025 financial results
- Unveil a new oral development candidate targeting an undrugged target for autoimmune and rheumatic diseases
- Review highlights and upcoming milestones of its immunology pipeline
The webcast will be accessible through registration and available for replay on the company's website under the Investors section.
Kymera Therapeutics (NASDAQ: KYMR) has initiated dosing in its BroADen Phase 1b clinical trial for KT-621, a first-in-class oral STAT6 degrader, targeting moderate to severe atopic dermatitis (AD). The trial will evaluate approximately 20 adult patients with once-daily dosing for 28 days, focusing on safety, tolerability, and clinical activity.
The company has completed SAD/MAD dosing in the Phase 1 healthy volunteer trial, with data expected in June 2025. The BroADen trial results are anticipated in Q4 2025. Additionally, Kymera plans to launch two parallel Phase 2b trials: one for AD in Q4 2025 and another for asthma in Q1 2026.
The BroADen study aims to demonstrate that STAT6 degradation in blood and skin by KT-621 produces effects similar to dupilumab in reducing Th2 biomarkers. The trial will assess clinical endpoints including Eczema Area and Severity Index (EASI) and pruritus numerical rating scale (NRS).
Kymera Therapeutics (NASDAQ: KYMR) has appointed Noah Goodman, M.B.A., as Chief Business Officer to lead business development strategy and activities. Goodman brings extensive life sciences industry experience, having previously served as President and Chief Business Officer at Chroma Medicine and nChroma Bio through their merger with Nvelop Therapeutics.
Prior to joining Kymera, Goodman held key positions at several biotech companies, including Executive Director roles at Cadent Therapeutics (later acquired by Novartis) and Seres Therapeutics, where he led collaborations and licensing transactions. His earlier experience includes business development at Spark Therapeutics and consulting at Easton Associates.
The appointment aligns with Kymera's mission to develop oral small molecule degrader medicines for immunological diseases and build a fully integrated biopharmaceutical company.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
